The breast cancer cells were (MCF7/p53 wild type (wt) and MDA-MB-231/p53 mutant (mt)) treated with MA242 at concentrations ranging from 0 to 2.5 μM over a 72-h period, followed by evaluation of cell viability (Figure 1A). This evidence concerns the gene TP53 and breast cancer.